Longeveron Inc. (LGVN) stock
LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.92−0.19 (-9.00%)
Close on Nov 18, 2026Market cap $61.21MP/E –Yield –
Longeveron cash
Cash and short-term investments held at the end of each period.
Longeveron's cash was $10.08M at Jun 30, 2026. For fiscal 2025 it was $4.66M, down 75.8% from the year before. The highest annual figure on record is $19.66M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.66M | -75.8% |
| FY2024 | Dec 31, 2024 | $19.23M | +258.7% |
| FY2023 | Dec 31, 2023 | $5.36M | -72.7% |
| FY2022 | Dec 31, 2022 | $19.66M | +97.3% |
| FY2021 | Dec 31, 2021 | $9.96M | +1120.9% |
| FY2020 | Dec 31, 2020 | $816.00K | -56.3% |
| FY2019 | Dec 31, 2019 | $1.87M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.08M | -2.5% |
| Q1 FY2026 | Mar 31, 2026 | $15.76M | +10.0% |
| Q4 FY2025 | Dec 31, 2025 | $4.66M | -75.8% |
| Q3 FY2025 | Sep 30, 2025 | $9.24M | -59.4% |
| Q2 FY2025 | Jun 30, 2025 | $10.33M | -16.5% |
| Q1 FY2025 | Mar 31, 2025 | $14.33M | +525.4% |
| Q4 FY2024 | Dec 31, 2024 | $19.23M | +258.7% |
| Q3 FY2024 | Sep 30, 2024 | $22.78M | +479.2% |
| Q2 FY2024 | Jun 30, 2024 | $12.38M | +350.5% |
| Q1 FY2024 | Mar 31, 2024 | $2.29M | -0.4% |
| Q4 FY2023 | Dec 31, 2023 | $5.36M | -72.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.93M | -80.6% |
| Q2 FY2023 | Jun 30, 2023 | $2.75M | -87.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.30M | -76.9% |
| Q4 FY2022 | Dec 31, 2022 | $19.66M | +3.6% |
| Q2 FY2022 | Jun 30, 2022 | $20.22M | -5.4% |
| Q1 FY2022 | Mar 31, 2022 | $22.13M | -9.5% |
| Q4 FY2021 | Dec 31, 2021 | $9.96M | +1120.9% |
| Q3 FY2021 | Sep 30, 2021 | $18.97M | +1260.8% |
| Q2 FY2021 | Jun 30, 2021 | $21.39M | +1189.2% |
| Q1 FY2021 | Mar 31, 2021 | $24.46M | +887.1% |
| Q4 FY2020 | Dec 31, 2020 | $816.00K | -56.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.39M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.66M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.48M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.87M | – |
See a number that looks wrong?